Exosome: from internal vesicle of the multivesicular body to intercellular signaling device
K Denzer, MJ Kleijmeer, HFG Heijnen… - Journal of cell …, 2000 - journals.biologists.com
Exosomes are small membrane vesicles that are secreted by a multitude of cell types as a
consequence of fusion of multivesicular late endosomes/lysosomes with the plasma …
consequence of fusion of multivesicular late endosomes/lysosomes with the plasma …
Dendritic cells: unique leukocyte populations which control the primary immune response
DNJ Hart - Blood, The Journal of the American Society of …, 1997 - ashpublications.org
It is now possible to grow DC-like cells in culture17-21 and extensive cell membrane
processes that are acquired late the first monoclonal antibodies (MoAbs) 22, 23 that react …
processes that are acquired late the first monoclonal antibodies (MoAbs) 22, 23 that react …
Engineered nucleic acids encoding a modified erythropoietin and their expression
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
D Boczkowski, SK Nair, D Snyder… - The Journal of …, 1996 - rupress.org
Immunization with defined tumor antigens is currently limited to a small number of cancers
where candidates for tumor rejection antigens have been identified. In this study we …
where candidates for tumor rejection antigens have been identified. In this study we …
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo
NC Fernandez, A Lozier, C Flament… - Nature medicine, 1999 - nature.com
Cytotoxic T lymphocytes and natural killer cells are essential effectors of anti-tumor immune
responses in vivo. Dendritic cells (DC)'prime'tumor antigen-specific cytotoxic T lymphocytes; …
responses in vivo. Dendritic cells (DC)'prime'tumor antigen-specific cytotoxic T lymphocytes; …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Engineered nucleic acids and methods of use thereof
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C (= O) C (NC (= O)
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
Modified polynucleotides for the production of biologics and proteins associated with human disease
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of secreted proteins
T Chakraborty, A De Fougerolles - US Patent 9,192,651, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
F Von Der Mülbe, I Hoerr, S Pascolo - US Patent 10,188,748, 2019 - Google Patents
The present invention relates to a pharmaceutical composi tion comprising a modified
mRNA that is stabilized by sequence modifications and optimized for translation. The …
mRNA that is stabilized by sequence modifications and optimized for translation. The …